Display options
Share it on

Kidney Int Rep. 2016 Sep;1(3):135-143. doi: 10.1016/j.ekir.2016.06.006.

Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.

Kidney international reports

Meghan E Sise, Jessica Wisocky, Ivy A Rosales, Donald Chute, Jacinta A Holmes, Kristin M Corapi, Jodie L Babitt, Jessica S Tangren, Nikroo Hashemi, Andrew L Lundquist, Winfred W Williams, David B Mount, Karin L Andersson, Helmut G Rennke, R Neal Smith, Robert Colvin, Ravi I Thadhani, Raymond T Chung

Affiliations

  1. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
  2. Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA.
  3. Department of Pathology, Massachusetts General Hospital, Boston, MA.
  4. Department of Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA.
  5. Renal Unit, Brigham and Women's Hospital, Boston, MA.
  6. Department of Pathology, Brigham and Women's Hospital, Boston, MA.

PMID: 27990496 PMCID: PMC5155703 DOI: 10.1016/j.ekir.2016.06.006

Abstract

Novel, all-oral interferon-free direct-acting antiviral agents have revolutionized the management of hepatitis C virus (HCV) infection by producing exceptional cure rates with minimal adverse events. While provocation or exacerbation of autoimmunity has been reported in HCV-infected patients receiving interferon, this phenomenon has not been reported in patients receiving interferon-free HCV therapy. We report the occurrence of three cases of lupus-like immune complex-mediated glomerulonephritis occurring shortly after exposure to sofosbuvir-based direct-acting antiviral therapies. In all three cases, renal function quickly improved with immunosuppression. However, two of the three patients developed infectious complications of immunosuppression and died. This is the first report of a lupus-like immune complex mediated glomerulonephritis occurring in the context of HCV eradication with all-oral direct-acting antiviral therapies.

References

  1. Kidney Int. 2003 Jun;63(6):2236-41 - PubMed
  2. J Virol. 2007 Sep;81(17):8953-66 - PubMed
  3. PLoS One. 2011;6(8):e23856 - PubMed
  4. Hepatology. 2016 Feb;63(2):408-17 - PubMed
  5. Curr HIV/AIDS Rep. 2015 Mar;12(1):68-78 - PubMed
  6. Exp Clin Transplant. 2014 Mar;12 Suppl 1:129-35 - PubMed
  7. World J Clin Cases. 2015 Aug 16;3(8):736-42 - PubMed
  8. Liver Transpl. 2016 Mar;22(3):281-6 - PubMed
  9. Hepatology. 2015 Apr;61(4):1145-53 - PubMed
  10. Rheumatology (Oxford). 2013 Nov;52(11):2041-7 - PubMed
  11. Ann Intern Med. 2006 May 16;144(10):735-41 - PubMed
  12. J Clin Rheumatol. 2008 Jun;14 (3):166-8 - PubMed
  13. Semin Arthritis Rheum. 2002 Dec;32(3):163-73 - PubMed
  14. Ann Intern Med. 2014 Mar 4;160(5):293-300 - PubMed
  15. Gastroenterology. 2016 Feb;150(2):419-29 - PubMed
  16. Ann Intern Med. 1991 Aug 1;115(3):178-83 - PubMed
  17. Clin J Am Soc Nephrol. 2010 Apr;5(4):607-15 - PubMed
  18. Clin Exp Immunol. 2003 Sep;133(3):404-13 - PubMed
  19. Kidney Int. 1983 Sep;24(3):377-85 - PubMed
  20. N Engl J Med. 1993 Feb 18;328(7):465-70 - PubMed
  21. J Autoimmun. 2015 Feb;57:60-5 - PubMed
  22. BMJ. 2014 Jul 07;348:g3308 - PubMed
  23. Am J Kidney Dis. 2004 Apr;43(4):617-23 - PubMed
  24. Hepatology. 2015 Oct;62(4):1004-12 - PubMed
  25. Nephrol Dial Transplant. 1999 Oct;14(10):2279-82 - PubMed

Publication Types

Grant support